BROWN MORGAN R 4
4 · Lipocine Inc. · Filed Dec 8, 2020
Insider Transaction Report
Form 4
Lipocine Inc.LPCN
BROWN MORGAN R
EVP and CFO
Transactions
- Sale
Common Stock
2020-12-04$1.57/sh−17,250$27,024→ 104,062 total - Exercise/Conversion
Common Stock
2020-12-04+57,500→ 121,312 total - Exercise/Conversion
Restricted Stock Unit
2020-12-04−57,500→ 57,500 totalExercise: $0.00From: 2020-12-04Exp: 2028-12-04→ Common Stock (57,500 underlying) - Exercise/Conversion
Restricted Stock Unit
2020-12-05−70,754→ 70,754 totalExercise: $0.00From: 2020-12-05Exp: 2029-12-05→ Common Stock (70,754 underlying) - Exercise/Conversion
Common Stock
2020-12-05+70,754→ 174,816 total
Footnotes (4)
- [F1]Represents shares of Lipocine Inc. common stock ("LPCN Common Stock") acquired upon the vesting of restricted stock units.
- [F2]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
- [F3]Represents the weighted average price of shares sold at a price that ranged from $1.54 - $1.60.
- [F4]Subject to vesting whereby 50% of the shares subject to the award will vest on the one year anniversary of December 4, 2019 and the remaining 50% of the shares subject to the award will vest on the two year anniversary of December 4, 2020.